Literature DB >> 6546405

A new approach to angiotensin antagonists: methylation of the tyrosine hydroxyl in angiotensin II.

M N Scanlon, J M Matsoukas, K J Franklin, G J Moore.   

Abstract

[Sar1, Tyr(Me)4]angiotensin II, synthesized by the solid phase method and purified by ion-exchange chromatography and reversed-phase HPLC, was found to inhibit the contractile response to angiotensin II in the rat isolated uterus and inhibit the pressor response to angiotensin II in the vagotomized ganglion-blocked rat. In the rat isolated uterus Schild plots gave a pA2 of 8.1, and a slope of 0.9 indicative of competitive inhibition. In the rat pressor assay, infusion of the analogue at a rate of 500ng/kg/min caused a parallel displacement of the dose-response curve to ANG II to the right. In contrast, the classical angiotensin inhibitor [Sar1, Ile8] ANG II appeared to demonstrate non-competitive inhibition in both the rat isolated uterus and the pressor assays. The phenolic hydroxyl of phenoxide anion of Tyr4 in angiotensin II appears to be critical for the activation of angiotensin receptors in smooth muscle. Alkylation of the tyrosine residue in angiotensin analogues provides a new route for the synthesis of potent competitive antagonists of angiotensin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6546405     DOI: 10.1016/0024-3205(84)90618-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action.

Authors:  Y J Liu; N P Shankley; N J Welsh; J W Black
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  A computer modeling postulated mechanism for angiotensin II receptor activation.

Authors:  M P Joseph; B Maigret; J C Bonnafous; J Marie; H A Scheraga
Journal:  J Protein Chem       Date:  1995-07

3.  The kinin B1 receptor antagonist des-Arg9-[Leu8]bradykinin: an antagonist of the angiotensin AT1 receptor which also binds to the AT2 receptor.

Authors:  D Pruneau; A Duvoid; J M Luccarini; P Bélichard; J C Bonnafous
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 4.  From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.

Authors:  John Matsoukas; Vasso Apostolopoulos; Anthony Zulli; Graham Moore; Konstantinos Kelaidonis; Kalliopi Moschovou; Thomas Mavromoustakos
Journal:  Molecules       Date:  2021-01-25       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.